Mexico

With an estimated annual growth rate of 10%, the Middle East is now consistently outpacing traditionally sought-after “pharmerging” heavyweights such as China and Brazil. The United Arab Emirates is at the center of this newfound momentum-asserting its own credentials as a prospective destination for big-ticket foreign investment in healthcare.

Away from the glare of publicity, a tranche of bold reforms in Canada, aimed at harmonizing the national health system and delivering value for money, are fast nearing completion.

Still motivated by its challenging, underdog past, Poland has strengthened its economic engine in Europe, where the nation’s pharmaceutical sector is increasingly pursuing enlightened approaches in areas such as market access and evidence-based decision-making.

The global importance of the Indian pharmaceutical industry and the affordable generic drugs it produces is indisputable. But despite its evolving international role, India’s domestic healthcare system remains underperforming and undercapitalized.

Three pivotal developments that occurred in 2017 illustrate the growing relevance and influence of the Swiss pharmaceutical and life sciences industry on the world stage. Companies in Switzerland are also playing innovative roles in reshaping the pharma value chain and contemporary paradigm of healthcare provision.

Despite having the tenth-largest pharma market in the world and being the birthplace of medical breakthroughs, from insulin to stem cells, Canada seems to be punching below its weight when it comes to health innovation. There are signs, however, that things may be changing as the nation looks to bulk back up.